VANDA PHARMACEUTICALS INC (VNDA)
Health Care · Specialty biopharmaceutical company focused on psychiatry, rare diseases, and oncology · NASDAQ
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in dermatology, rare diseases, and oncology.
What VANDA PHARMACEUTICALS INC does
Vanda Pharmaceuticals is a biopharmaceutical company developing and commercializing innovative therapies for high unmet medical needs. The company operates a commercial portfolio of four approved products: Fanapt for schizophrenia and bipolar disorder, HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis syndrome, PONVORY for relapsing multiple sclerosis, and NEREUS for motion-induced nausea. The pipeline includes additional formulations and indications for current products plus novel molecules targeting psychiatric disorders, dermatology, rare diseases, and oncology.
Themes: ["Schizophrenia and bipolar disorder treatment","Sleep disorders and circadian rhythm management","Multiple sclerosis","Dermatology and rare skin diseases","Psychiatry and anxiety disorders","Oncology and hematologic malignancies","Rare genetic diseases","Pharmacogenetics and pharmacogenomics"]
Fundamentals
- Price$6.38 as of 2026-07-09 close
- Market cap$376M as of 2026-07-10
- 1-year return+27.1% as of 2026-07-09 close
- Net margin-110.0% as of 2026-07-10
- Gross margin+94.2% as of 2026-07-10
- ROE-61.4% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)+8.2% as of 2026-07-10
- Revenue CAGR (3y)-5.3% SEC XBRL
- Beta0.61 as of 2026-07-10
Key risks (from latest filing)
["Heavy dependence on four commercial products for revenue generation; loss of exclusivity or generic competition could materially impact sales, particularly for HETLIOZ which faces existing and potential generic competition","Company is currently unprofitable with negative net margin of -109.99%; sustained ability to fund R&D and commercialization depends on capital availability and successful product approvals","Clinical development risks including potential failure to obtain FDA approval for pipeline candidates (BYSANTI for MDD, NEREUS for additional indications, imsidolimab for GPP) and delays in clinical trial timelines"]
Competitors & peers
- Otsuka Pharmaceutical (schizophrenia antipsychotics)
- Eli Lilly (bipolar disorder, antipsychotics)
- Johnson & Johnson (antipsychotics, multiple sclerosis)
- Biogen (multiple sclerosis)
- Celgene (dermatology, hematologic malignancies)
- Novartis (multiple sclerosis, psychiatry)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.